Ken Griffin
SYRE icon

Ken Griffin’s Spyre Therapeutics SYRE Stock Holding History

Ken Griffin’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.45M Buy
108,135
+44,231
+69% +$1.67M ﹤0.01% 4206
2025
Q4 		$2.09M Buy
+63,904
New +$1.67M ﹤0.01% 5818
2025
Q2 		– Sell
-130,884
Closed -$2.11M – 15014
2025
Q1 		$2.11M Sell
130,884
-948,423
-88% -$19.7M ﹤0.01% 5436
2024
Q4 		$25.1M Buy
1,079,307
+371,721
+53% +$10.9M ﹤0.01% 1919
2024
Q3 		$20.8M Hold
707,586
– – ﹤0.01% 2012
2024
Q2 		$16.6M Sell
707,586
-4
-0% -$135 ﹤0.01% 2189
2024
Q1 		$26.8M Buy
707,590
+130,879
+23% +$3.79M 0.01% 1778
2023
Q4 		$12.4M Buy
576,711
+479,658
+494% +$6.61M ﹤0.01% 2570
2023
Q3 		$1.19M Buy
+97,053
New +$1.28M ﹤0.01% 6215
2023
Q1 		– Sell
-619
Closed -$6.96K – 15500
2022
Q4 		$6.96K Sell
619
-1,812
-75% -$32.6K ﹤0.01% 13867
2022
Q3 		$32K Sell
2,431
-6,657
-73% -$82.2K ﹤0.01% 11872
2022
Q2 		$115K Buy
9,088
+6,151
+209% +$216K ﹤0.01% 11274
2022
Q1 		$169K Buy
+2,937
New +$247K ﹤0.01% 11716
2021
Q1 		– Sell
-1,349
Closed -$259K – 13699
2020
Q4 		$265K Sell
1,349
-552
-29% -$114K ﹤0.01% 9277
2020
Q3 		$337K Buy
1,901
+775
+69% +$143K ﹤0.01% 7937
2020
Q2 		$261K Buy
1,126
+178
+19% +$33.9K ﹤0.01% 8135
2020
Q1 		$110K Buy
948
+368
+63% +$62.6K ﹤0.01% 8568
2019
Q4 		$111K Buy
+580
New +$114K ﹤0.01% 8504
2019
Q3 		– Sell
-1,189
Closed -$203K – 9739
2019
Q2 		$203K Sell
1,189
-3,579
-75% -$619K ﹤0.01% 8169
2019
Q1 		$960K Buy
+4,768
New +$994K ﹤0.01% 5664
2016
Q3 		– Sell
-514
Closed -$62K – 7760
2016
Q2 		$62K Buy
+514
New +$98.5K ﹤0.01% 6356

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ken Griffin's SYRE Position: Q1 2026 in Review

Ken Griffin increased its Spyre Therapeutics (SYRE) stake by 69% in Q1 2026, buying an estimated $1.67M and bringing the position to 108,135 shares worth $5.45M. The position accounts for ﹤0.01% of the portfolio, ranked #4206.

Ken Griffin first reported a position in SYRE in Q2 2016 and has held it in 21 quarters since. The position peaked at $26.8M in Q1 2024. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Ken Griffin held 108,135 shares of Spyre Therapeutics worth $5.45M as of Q1 2026.
  • Ken Griffin bought 44,231 Spyre Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Spyre Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4206 holding.
  • Ken Griffin first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 21 quarters since.
  • Ken Griffin's Spyre Therapeutics position peaked at $26.8M in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.